利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.03 秒)

    Early diagnosis of conformational diseases
    2.
    发明授权
    Early diagnosis of conformational diseases 有权
    构象疾病的早期诊断

    公开(公告)号：US07351526B2

    公开(公告)日：2008-04-01

    申请号：US10332370

    申请日：2001-06-13

    申请人： Claudio Soto ,  Gabriella Saborio

    发明人： Claudio Soto ,  Gabriella Saborio

    IPC分类号： A61K38/00 ,  C07K16/00

    CPC分类号： G01N33/6896 ,  G01N2800/2828

    摘要： A method for the diagnosis or detection of conformational diseases by assaying for a marker (the pathogenic conformer) of such diseases in a sample is described, which method comprises a cyclic amplification system to increase the levels of the pathogenic conformer which causes such diseases. In particular, such transmissible conformational diseases may be prion encephalopathies. Assays, diagnostic kits and apparatus based on such methods are also disclosed.

    摘要翻译： 描述了通过测定样品中这种疾病的标志物（致病构象异构体）来诊断或检测构象疾病的方法，该方法包括循环扩增系统以增加引起这种疾病的致病性构象异构体的水平。 特别地，这种传播性构象疾病可能是朊病毒性脑病。 还公开了基于这些方法的测定，诊断试剂盒和仪器。

    Use of prion conversion modulating agents
    4.
    发明授权
    Use of prion conversion modulating agents 有权
    使用朊病毒转化调节剂

    公开(公告)号：US07598046B2

    公开(公告)日：2009-10-06

    申请号：US10560978

    申请日：2004-06-18

    申请人： Claudio Soto-Jara ,  Kinsey Maundrell

    发明人： Claudio Soto-Jara ,  Kinsey Maundrell

    IPC分类号： G01N33/53 ,  A61K49/00 ,  A61K39/395 ,  A61K39/00

    CPC分类号： A61K31/00 ,  C07K16/18 ,  G01N33/92 ,  G01N2333/4709

    摘要： The use of Apolipoprotein B, Apolipoprotein E, fragments and mimetics thereof is provided for diagnostic, detection, prognostic and therapeutic applications In prion diseases. More specifically, the invention provides the use of Apolipoprotein B or fragments thereof for modulating or identifying modulators of the prion protein replication which are implicated in the pathogenesis of transmissible spongiform encephalopathics and other prion diseases.

    摘要翻译： 提供载体载脂蛋白B，载脂蛋白E，其片段和模拟物用于诊断，检测，预后和治疗应用在朊病毒疾病中。 更具体地，本发明提供载体载体蛋白B或其片段用于调节或鉴定涉及传染性海绵状脑病和其他朊病毒疾病的发病机理的朊病毒蛋白复制调节剂。

    Pharmaceutically active sulfonyl hydrazide derivatives
    8.
    发明授权
    Pharmaceutically active sulfonyl hydrazide derivatives 失效
    药物活性磺酰肼衍生物

    公开(公告)号：US07432286B1

    公开(公告)日：2008-10-07

    申请号：US10088074

    申请日：2000-09-28

    申请人： Stephen Arkinstall ,  Serge Halazy ,  Dennis Church ,  Montserrat Camps ,  Thomas Rueckle ,  Jean-Pierre Gotteland ,  Marco Biamonte

    发明人： Stephen Arkinstall ,  Serge Halazy ,  Dennis Church ,  Montserrat Camps ,  Thomas Rueckle ,  Jean-Pierre Gotteland ,  Marco Biamonte

    IPC分类号： C07D417/12 ,  C07D213/74 ,  A61K31/44

    CPC分类号： C07D213/74 ,  C07D409/12 ,  C07D409/14 ,  C07D417/12 ,  C07D417/14

    摘要： The present invention is related to sulfonyl hydrazide derivatives for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such sulfonyl hydrazide derivatives. Said sulfonyl hydrazide derivatives are efficient modulators of the JNK pathway, they are in particular efficient inhibitors of JNK 2 and 3. The present invention is furthermore related to novel sulfonyl hydrazide derivatives as well as to methods of their preparation. In Formula (I) Ar1 and Ar2 are independently from each other an unsubstituted or substituted aryl or beteroaryl group, X1 and X2 are independently from each other O or S; R1, R2, R3 are independently from each other hydrogen or a C1-C6-alkyl substituent or R1 forms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with Ar1; or R2 and R3 form a substituted or unsubstituted 5-6-membered saturated or unsaturated ring; n is an integer from 0 to 5; G is selected from a group comprising or consisting of an unsubstituted or substituted 4-8 membered heterocycle containing at least one heteroatom, or G is a substituted or unstibstituted C1-C6-alkyl group.

    摘要翻译： 本发明涉及用作药物活性化合物的磺酰肼衍生物以及含有这种磺酰肼衍生物的药物制剂。 所述磺酰肼衍生物是JNK途径的有效调节剂，它们特别是JNK 2和3的有效抑制剂。本发明还涉及新型磺酰肼衍生物及其制备方法。 在式（I）中，Ar 1和Ar 2彼此独立地为未取代或取代的芳基或双芳基，X 1和X 2独立地为 SUP> 2 彼此独立地为O或S; R 1，R 2，R 3，3彼此独立地为氢或C 1 -C 3 > 6个 - 烷基取代基或R 1'与Ar 1形成取代或未取代的5-6元饱和或不饱和的环; 或R 2和R 3形成取代或未取代的5-6元饱和或不饱和环; n为0〜5的整数， G选自包含至少一个杂原子的未取代或取代的4-8元杂环或由其组成，或G是取代或未取代的C 1 -C 6 烷基。